Mental Comorbidity in Rheumatic Diseases

Abstract

In this review, we summarise the most relevant studies in a PubMed Search term “mental disorders and rheumatic disease” in the last 15 years. Mental disorders such as depression and anxiety are common in people with rheumatic diseases. Treating these comorbidities can improve the patientʼs quality of life. The high prevalence of symptoms of psychiatric disorders is a challenge for rheumatologists, especially with regard to the differentiation of possible psychiatric components in rheumatological diseases. Screening for psychiatric problems in patients with rheumatic diseases should be evaluated as soon as possible, as these can have a major influence on the perception of pain and physical functioning status from the outset. Mental health disorders are seen as a risk factor for poor patient outcomes, as patients may not adhere to medical treatments. The potential side effects of biological agents can increase patient anxiety and affect adherence to therapy. Therefore, interdisciplinary care would be of great advantage in the treatment of rheumatic patients with psychological comorbidities.

Zusammenfassung

In dieser Übersicht wurden die wichtigsten Studien einer PubMed-Suche zum Thema „Psychische Störungen und rheumatische Erkrankungen“ der letzten 15 Jahre zusammengefasst. Psychische Störungen wie Depression- und Angsterkrankungen sind bei Personen mit rheumatischen Erkrankungen häufig. Durch eine Behandlung dieser Komorbiditäten kann die Lebensqualität der Patienten verbessert werden. Die hohe Prävalenz von Symptomen psychiatrischer Störungen ist eine Herausforderung für Rheumatologen, insbesondere im Hinblick auf die Differenzierung möglicher psychischer Komponenten bei rheumatischen Beschwerden. Das Screening auf psychiatrische Probleme bei Patienten mit entzündlich-rheumatischen Erkrankungen sollte so bald wie möglich evaluiert werden, da diese von Anfang an einen großen Einfluss auf die Wahrnehmung von Schmerzen und den körperlichen Funktionsstatus haben können. Psychische Störungen sind als Risikofaktor für ein schlechtes Outcome bei Patienten anzusehen, da die Patienten sich möglicherweise nicht an medizinische Behandlungen halten. Die möglichen Nebenwirkungen von biologischen Wirkstoffen können das Angstniveau der Patienten erhöhen und die Therapietreue beeinflussen. Von daher hätte eine interdisziplinäre Versorgung einen großen Vorteil bei der Behandlung von rheumatischen Patienten mit psychischen Komorbiditäten

Key words

depression - anxiety - bipolar disorder - schizophrenia - DMARDs

Schlüsselwörter

bipolare Störung - Schizophrenie - DMARDs - Angst Störungen - depressive Störungen

Publication History

Article published online:
13 April 2021

• References

• 1 Englbrecht M, Alten R, Aringer M. et al. New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study.PLoS One 2019; 14: e0217412 DOI: 10.1371/journal.pone.0217412.
• 2 Geenen R, Newman S, Bossema ER. et al. Psychological interventions for patients with rheumatic diseases and anxiety or depression Best Pract Res Clin Rheumatol 2012; 26: 305-319 DOI: 10.1016/j.berh.2012.05.004.
• 3 Malavia TA, Chaparala S, Wood J. et al. Generating testable hypotheses for schizophrenia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data NPJ Schizophr 2017; 24: 11 DOI: 10.1038/s41537-017-0010-z.
• 4 Baerwald C, Manger B, Hueber A. Depression as comorbidity of rheumatoid arthritis. Z Rheumatol 2019; 78: 243-248 DOI: 10.1007/s00393-018-0568-5.
• 5 Covic T, Cumming SR, Pallant JF. et al. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS) BMC Psychiatry. 2012; 246 DOI: 10.1186/1471-244X-12-6.
• 6 Freier D, Englbrecht M, Höhne-Zimmer V. et al. Higher prevalence of depressive and anxiety symptoms in early arthritis patients in comparison to the normal population Z Rheumatol 2019; 78: 820-831 DOI: 10.1007/s00393-018-0571-x.
• 7 Morf H, da Rocha Castelar-Pinheiro G, Vargas-Santos AB. et al. Impact of clinical and psychological factors associated with depression in patients with rheumatoid arthritis: comparative study between Germany and Brazil Clin Rheumatol. 2020; DOI: 10.1007/s10067-020-05470-0. Online ahead of print. PMID: 33104946
• 8 Meesters JL, Petersson IF, Bergman S. et al. Ann Bremander Sociodemographic and disea-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort Clin Rheumatol 2014; 33: 1649-1656 DOI: 10.1007/s10067-014-2699-7.
• 9 Shen CC, Hu LY, Yang AC. et al. Risk of Psychiatric Disorders following Ankylosing Spondylitis: A Nationwide Population-based Retrospective Cohort Study J Rheumatol 2016; 43: 625-631 DOI: 10.3899/jrheum.150388.
• 10 Kwan K, Katz P, Touma Z. The Assessment of Anxiety andepression and its Associated Factors in SLE Curr Rheumatol Rev 2019; 15: 90-98 DOI: 10.2174/1573397114666180926101513.
• 11 Lisitsyna TA, Veltishchev DY, Seravina OF. et al. Comparative analysis ofnxiety-depressive spectrum disorders in patients with rheumatic diseases Ter Arkh 2018; 11 90 30-37 DOI: 10.26442/terarkh201890530-37.
• 12 Hsieh MC, Hsu CW, Lu MC. et al. Increased risks of psychiatric disorders in patients with primary Sjögren’s syndrome – a secondary cohort analysis of nationwide, population-based health claim data Affiliations Expand Clin Rheumatol 2019; 38: 3195-3203 DOI: 10.1007/s10067-019-04705-z.
• 13 Calandre EP, Villademoros FR, Slim M. Suicidal behaviors in patients with rheumatic diseases: a narrative review Rheumatol Int 2018; 38: 537-548 DOI: 10.1007/s00296-017-3909-9.
• 14 Leon L, Abasolo L, Redondo M. et al. Negative affect in systemic sclerosis Rheumatol Int 2014; 34: 597-604 DOI: 10.1007/s00296-013-2852-7.
• 15 Charoenngam N, Ponvilawan B, Ungprasert P. Patients with rheumatoid arthritis have a higher risk of bipolar disorder: A systematic review and meta-analysis Psychiatry Res 2019; 282: 112484 DOI: 10.1016/j.psychres.2019.112484.
• 16 Farhi A, Cohen AD, Shovman O. et al. Bipolar disorder associated with rheumatoid arthritis: A case-control study J Affect Disord 2016; 1: 287-289 DOI: 10.1016/j.jad.2015.09.058.
• 17 Hsu CC, Chen SC, Liu CJ. et al. Rheumatoid arthritisnd the risk of bipolar disorder: a nationwide population-based study PLoS One 2014; 17: e107512 DOI: 10.1371/journal.pone.0107512.
• 18 Wallace DJ, Gotto J. Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia Semin Arthritis Rheum 2008; 37: 256-259 DOI: 10.1016/j.semarthrit.2007.04.008.
• 19 Chung KH, Huang CC, Lin HC. Increased risk of gout among patients with bipolar disorder: a nationwide population-based study Psychiatry Res 2010; 180: 147-150 DOI: 10.1016/j.psychres.2009.07.012.
• 20 Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review Schizophr Res 1992; 6: 181-192 DOI: 10.1016/0920-9964(92)90001.
• 21 Marrie RA, Hitchon CA, Walld R. et al. Canadian Institutes of Health Research Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease Increased Burden of Psychiatric Disorderin Rheumatoid Arthritis Arthritis Care Res (Hoboken) 2018; 70: 970-978 DOI: 10.1002/acr.23539.
• 22 Euesden J, Breen G, Farmer A. et al. The relationship between schizophrenia and rheumatoid arthritis revisited: genetic and epidemiological analyses Am J Med Genet B Neuropsychiatr Genet 2015; 168B: 81-88 DOI: 10.1002/ajmg.b.32282.
• 23 Sellgren C, Frisell T, Lichtenstein P. et al. The association between schizophrenia and rheumatoid arthritis: a nationwide population-based Swedish study on intraindividual and familial risks Schizophr Bull 2014; 40: 1552-1559 DOI: 10.1093/schbul/sbu054.
• 24 Wang LY, Chen SF, Chiang JH. et al. Autoimmune diseases are associated with an increased risk of schizophrenia: A nationwide population-based cohort study Schizophr Res 2018; 202: 297-302 DOI: 10.1016/j.schres.2018.06.033.
• 25 Colpo GD, Leboyer M, Dantzer R. et al. Immune-based strategies for mood disorders: facts and challenges Expert Rev Neurother 2018; 18: 139-152 DOI: 10.1080/14737175.2018.1407242.
• 26 Varan Ö, Babaoğlu H, Göker B. Associations between Depressive Disorders and Inflammatory Rheumatic Diseases Curr Top Med Chem 2018; 18: 1395-1401 DOI: 10.2174/1568026618666180516100805.
• 27 Schmidt FM, Schröder T, Kirkby KC. et al. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression Psychiatry Res 2016; 239: 85-91 DOI: 10.1016/j.psychres.2016.02.052.
• 28 Müller N. Immunological aspects of the treatment of depression and schizophrenia Dialogues Clin Neurosci 2017; 19: 55-63 DOI: 10.31887/DCNS.2017.19.1/nmueller.
• 29 Crespi BJ, Thiselton DL. Comparative immunogenetics of autism and schizophrenia Genes Brain Behav 2011; 10: 689-701 DOI: 10.1111/j.1601-183X.2011.00710.x.
• 30 Zamanpoor M, Ghaedi H, Omrani MD. The genetic basis for the inverse relationship between rheumatoid arthritis and schizophrenia Mol Genet Genomic Med 2020; e1483 DOI: 10.1002/mgg3.1483.
• 31 Lee SH, Byrne EM, Hultman CM. et al. New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis Int J Epidemiol 2015; 44: 1706-1721 DOI: 10.1093/ije/dyv136.
• 32 Matcham F, Ali S, Irving K. et al. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study BMC Musculoskelet Disord 2016; 17: 155 DOI: 10.1186/s12891-016-1011-1.
• 33 DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence Arch Intern Med 2000; 160: 2101-2107 DOI: 10.1001/archinte.160.14.2101.
• 34 Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways Nat Rev Rheumatol 2016; 12: 532-542 DOI: 10.1038/nrrheum.2016.112.
• 35 Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis Semin Arthritis Rheum 2017; 47: 351-360 DOI: 10.1016/j.semarthrit.2017.05.010.
• 36 Bagnato G, De Filippis LG, Caliri AG. et al. Comparation of levels of anxiety and depression in patients with autoimmune and chronic-degenerative rheumatic: preliminary data Reumatismo 2006; 58: 206-211 DOI: 10.4081/reumatismo.2006.206.
• 37 Haupt M. Psychiatric disorders in rheumatic diseases, as exemplified by systemic lupus erythematosus (SLE) Z Rheumatol 2004; 63: 122-130 DOI: 10.1007/s00393-004-0618-z.
• 38 Brown ES, Vera E, Frol AB. et al. Effects of chronic prednisone therapy on mood and memory J Affect Disord 2007; 99: 279-283 DOI: 10.1016/j.jad.2006.09.004.
• 39 Bartoli F, Crocamo C, Clerici M. et al. Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials Br J Psychiatry 2017; 210: 10-15 DOI: 10.1192/bjp.bp.115.180281.
• 40 Jahangard L, Soroush S, Haghighi M. et al. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder Eur Neuropsychopharmacol 2014; 24: 1210-1221 DOI: 10.1016/j. euroneuro.2014.05.013.
• 41 Baune BT. Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?. Curr Top Behav Neurosci 2017; 31: 303-319 DOI: 10.1007/7854_2016_19.
• 42 Faridhosseini F, Sadeghi R, Farid L. et al. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials Hum Psychopharmacol 2014; 29: 216-223 DOI: 10.1002/hup.2401.
• 43 Bai S, Guo W, Feng Y. et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials J Neurol Neurosurg Psychiatry 2020; 91: 21-32 DOI: 10.1136/jnnp-2019-320912.
• 44 Andrade C. Antidepressant augmentation with anti-inflammatory agents J Clin Psychiatry 2014; 75: 975-977 DOI: 10.4088/JCP.14f09432.
• 45 Raison CL, Rutherford RE, Woolwine BJ. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers JAMA Psychiatry 2013; 70: 31-41 DOI: 10.1001/2013.jamapsychiatry.4.
• 46 Hider SL, Tanveer W, Brownfield A. et al. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic Rheumatology (Oxford) 2009; 48: 1152-1154 DOI: 10.1093/rheumatology/kep170.
• 47 Fond G, Hamdani N, Kapczinski F. et al. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review Acta Psychiatr Scand 2014; 129: 163-179 DOI: 10.1111/acps.12211.
• 48 De Oliveira Ribeiro NP, de Mello Schier AR, Ornelas AC. et al. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs Compr Psychiatry 2013; 54: 1185-1189 DOI: 10.1016/j.comppsych.2013.05.010.
• 49 Ziarko M, Siemiątkowska K, Sieński M. et al. Mental Health and Rheumatoid Arthritis: Toward Understanding the Emotional Status of People with Chronic Disease Biomed Res Int. 2019: 1473925. DOI: 10.1155/2019/1473925
• 50 Luke W. Desilet. et al. Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis. ACR Open Rheumatol 2020; 2: 555-564 DOI: 10.1002/acr2.11175. Epub 2020 Sep 13
• 51 Pehlivan Y, Orucoglu N, Pehlivan S. et al. Patients’ concerns regarding biological agents in rheumatology Int J Rheum Dis 2018; 21: 1219-1226 DOI: 10.1111/1756.